Janssen seeks US FDA approval for teclistamab to treat patients with R/R multiple myeloma
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma.
Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.
“Despite all the gains that have been made in treating multiple myeloma, the unmet need still remains very high. Our relentless pursuit of treatments for this disease continues with the same sense of urgency that we have always had,” said Peter Lebowitz, M.D., Ph.D., global therapeutic area head, oncology, janssen research & development, LLC. “We look forward to working with the FDA in their review of our teclistamab submission.”
Lees dit artikel verder op: Janssen seeks US FDA approval for teclistamab to treat patients with R/R multiple myeloma (pharmabiz.com)
